Drugs / PT20
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT02151643 | May 2014 → Mar 2015 | hyperphosphatemia | Phosphate Therapeutics | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PT20 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02151643 ↗ |
| Known as | ferric iron oxide adipate | “PT20 (ferric iron oxide adipate) is an investigational molecule engineered to offer enhanced phosphate-binding properties relative to other phosphate binders.” PMID 32651955 ↗ Jul 2021 |
| Route | Oral | “28 days of oral PT20 treatment” PMID 32651955 ↗ Jul 2021 |